BioLineRx Ltd.
BLRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $684 | $4,033 | $1,218 | $3,606 |
| - Cash | $10 | $4 | $11 | $13 |
| + Debt | $15 | $12 | $12 | $5 |
| Enterprise Value | $688 | $4,041 | $1,219 | $3,598 |
| Revenue | $29 | $5 | $0 | $0 |
| % Growth | 502.9% | – | – | – |
| Gross Profit | $20 | $1 | $0 | $0 |
| % Margin | 68% | 23.1% | – | – |
| EBITDA | $4 | -$57 | -$29 | -$24 |
| % Margin | 13.5% | -1,189.3% | – | – |
| Net Income | -$9 | -$61 | -$25 | -$27 |
| % Margin | -31.9% | -1,262.8% | – | – |
| EPS Diluted | -0.12 | -0.94 | -0.48 | -0.61 |
| % Growth | 87.2% | -95.8% | 21.3% | – |
| Operating Cash Flow | -$44 | -$23 | -$26 | -$24 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$44 | -$23 | -$27 | -$24 |